KYOWA HAKKO KIRIN CO LTD |
End-of-day quote
Other stock markets
|
||
| - EUR | - |
|
| 08/04 | U.S. FDA declines to approve Supernus' drug-device combination for Parkinson's disease | RE |
| 03/04 | Kyowa Kirin Buys Back 4 Billion Yen Worth of Shares in March | MT |
| Sales 2024 * | 471B 3.01B 2.81B 251B | Sales 2025 * | 483B 3.09B 2.89B 258B | Capitalization | 1,407B 9.02B 8.41B 752B |
|---|---|---|---|---|---|
| Net income 2024 * | 66.51B 426M 398M 35.54B | Net income 2025 * | 72.93B 467M 436M 38.98B | EV / Sales 2024 * | 2.29 x |
| Net cash position 2024 * | 330B 2.11B 1.97B 176B | Net cash position 2025 * | 361B 2.31B 2.16B 193B | EV / Sales 2025 * | 2.17 x |
| P/E ratio 2024 * |
21
x | P/E ratio 2025 * |
19.1
x | Employees | - |
| Yield 2024 * |
2.21% | Yield 2025 * |
2.31% | Free-Float | 45.89% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
More news
| Managers | Title | Age | Since |
|---|---|---|---|
| Director of Finance/CFO | - | 01/86/01 | |
Masashi Miyamoto
PSD | President | 64 | 01/85/01 |
| Chief Tech/Sci/R&D Officer | 62 | 01/10/01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Takashi Oyamada
BRD | Director/Board Member | 68 | 01/21/01 |
Yoshihisa Suzuki
BRD | Director/Board Member | 68 | 01/22/01 |
| Director/Board Member | 66 | 01/08/01 |
Kyowa Kirin Co., Ltd. specializes in the development, manufacturing and marketing of pharmaceutical and biochemical products. Net sales break down by source of revenue as follows:
- sales of pharmaceutical products (92.6%): prescription products for anemia, cancers, immune and nephrology diseases treatment;
- sales of licenses (7.4%).
At the end of 2021, the group had 3 production sites located in Japan (2) and China.
Net sales break down geographically as follows: Japan (60.9%), Asia (9%), Americas (16.3%) and Europe (13.8%).
Sector
Pharmaceuticals
Calendar
07/05/2024
- Q1 2024 Earnings Release
Related indices
| 1st Jan change | Capi. | |
|---|---|---|
| +4.06% | 70.44B | |
| -14.44% | 4.75B | |
| +41.60% | 4.5B | |
| +5.96% | 3.85B | |
| +23.46% | 2.38B | |
| -19.32% | 2.34B | |
| -27.04% | 2.2B | |
| +7.97% | 1.96B | |
| -0.50% | 1.64B |
